Want to join the conversation?
$JKHY said that revenue growth will be slowed in FY17, hurt by the sale of Alogent business, which represented $28.4MM of revenue in FY16. The expected significant decrease in deconversion fees in FY17 is also considered as a headwind by the company. $JKHY does not anticipate losing any large deals in FY17.
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.